<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/"><channel><title>心血管出版物</title><link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;v=2.17.9.post6+86293ac&amp;utm_source=Chrome&amp;utm_medium=rss&amp;ff=202310071807 12&amp; utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;utm_campaign=出版-2<description>心血管亮点：PubMed 的最新结果</description><atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;v=2.17.9.post6+86293ac&amp;utm_source=Chrome&amp;utm_medium=rss&amp;ff=20231007180712&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;utm_campaign=pubmed-2" rel="self"></atom:link><docs> http://www.rssboard.org/rss-specification</docs><generator> PubMed RSS 源 (2.17.9.post6+86293ac)</generator><language> zh</language><lastbuilddate> 2023 年 10 月 7 日，星期六 22:07:13 +0000</lastbuilddate><pubDate> Sat, 07 Oct 2023 06:00:00 -0400</pubDate><ttl> 120</ttl><item><title>三尖瓣学术研究联盟对三尖瓣反流的定义和试验终点</title><link/>https://pubmed.ncbi.nlm.nih.gov/37804294/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231007180712&amp;v=2.17.9.post6+86293ac<description>随着多项自然史研究显示，即使在调整了多种合并症之后，三尖瓣反流 (TR) 患者的病理生理学、病因、治疗和结果的兴趣也随之增长，这些研究表明，随着 TR 严重程度的增加，结果也会逐渐恶化。瓣膜手术与高院内死亡率相关，导致经导管治疗方案的发展。第一个三尖瓣手术的目的... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol。2023 年 9 月 28 日：S0735-1097(23)06403-3。doi：10.1016/j.jacc.2023.08.008。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">随着多项自然史研究显示，即使在调整了多种合并症之后，三尖瓣反流 (TR) 患者的病理生理学、病因、治疗和结果的兴趣也随之增长，这些研究表明，随着 TR 严重程度的增加，结果也会逐渐恶化。瓣膜手术与高院内死亡率相关，导致经导管治疗方案的发展。第一份三尖瓣学术研究联盟文件的目的是标准化疾病病因和严重程度的定义，以及以下试验的终点：旨在解决我们在 TR 患者识别和管理方面的知识差距。标准化试验终点应提供一致性，并能够在临床试验之间进行有意义的比较。第二份三尖瓣学术研究联盟文件将重点关注进一步定义试验终点，并将讨论试验设计选项。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37804294/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231007180712&v=2.17.9.post6+86293ac">37804294</a> | DOI： <a href=https://doi.org/10.1016/j.jacc.2023.08.008>10.1016/j.jacc.2023.08.008</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37804294</guid><pubDate> Sat, 07 Oct 2023 06:00:00 -0400</pubDate><dc:creator>丽贝卡·T·哈恩</dc:creator><dc:creator>马修·K·劳勒</dc:creator><dc:creator>查尔斯·J·戴维森</dc:creator><dc:creator>维奈·巴德瓦尔</dc:creator><dc:creator>安娜桑尼诺</dc:creator><dc:creator>欧内斯特·斯皮策</dc:creator><dc:creator>菲利普·鲁兹</dc:creator><dc:creator>布莱恩·R·林德曼</dc:creator><dc:creator>严·托皮尔斯基</dc:creator><dc:creator>苏珊娜·J·巴伦</dc:creator><dc:creator>斯科特·查德登</dc:creator><dc:creator>奥马尔·K·哈利克</dc:creator><dc:creator>吉尔伯特·HL·唐</dc:creator><dc:creator>毛里齐奥·塔拉马索</dc:creator><dc:creator>保罗·格雷伯恩</dc:creator><dc:creator>路易吉·巴达诺</dc:creator><dc:creator>乔纳森·莱普西克</dc:creator><dc:creator>乔安·林登菲尔德</dc:creator><dc:creator>史蒂芬·温德克</dc:creator><dc:creator>斯里坎特·韦穆拉帕利</dc:creator><dc:creator>比约恩·雷德福斯</dc:creator><dc:creator>玛丽亚·C·阿鲁</dc:creator><dc:creator>大卫·J·科恩</dc:creator><dc:creator>何塞普·罗德斯·卡包</dc:creator><dc:creator>戈拉夫·艾拉瓦迪</dc:creator><dc:creator>迈克尔·麦克</dc:creator><dc:creator>奥里·本-耶胡达</dc:creator><dc:creator>马丁·B·莱昂</dc:creator><dc:creator>约尔格·豪斯莱特</dc:creator><dc:creator>TVARC指导委员会</dc:creator><dc:date>2023-10-07</dc:date><dc:source>美国心脏病学会杂志</dc:source><dc:title>三尖瓣学术研究联盟对三尖瓣反流的定义和试验终点</dc:title><dc:identifier>下午:37804294</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.08.008</dc:identifier></item><item><title> Mavacamten：用于治疗梗阻性肥厚性心肌病的一流肌球蛋白抑制剂</title><link/>https://pubmed.ncbi.nlm.nih.gov/37804245/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231007180712&amp;v=2.17.9.post6+86293ac<description> Mavacamten 是美国食品和药物管理局批准的一流、靶向、心脏特异性肌球蛋白抑制剂，用于治疗患有纽约心脏协会 II 级和 III 级梗阻性肥厚性心肌病 (oHCM) 的成人患者。针对过度收缩表型，该表型在疾病的病理生理学中起着至关重要的作用。在 2 期和 3 期临床试验中，mavacamten 耐受性良好，左心室流出量减少...... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 年 10 月 7 日：ehad637。doi：10.1093/eurheartj/ehad637。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> Mavacamten 是美国食品和药物管理局批准的一流、靶向、心脏特异性肌球蛋白抑制剂，用于治疗患有纽约心脏协会 II 级和 III 级梗阻性肥厚性心肌病 (oHCM) 的成人患者。针对过度收缩表型，该表型在疾病的病理生理学中起着至关重要的作用。在 2 期和 3 期临床试验中，mavacamten 耐受性良好，可降低左心室流出道梯度，改善运动能力和症状，并与改善相关其他临床相关参数，例如患者报告的结果和循环生物标志物。此外，mavacamten 治疗与多模态成像研究中有利的心脏重塑证据相关。Mavacamten 大大降低了 oHCM 和室间隔复位治疗候选者的指南资格。药物难治性症状。在本文中，回顾了 mavacamten 在有症状 oHCM 患者中已完成和正在进行的临床研究的可用疗效和安全性数据。长期扩展研究可能有助于解决与 mavacamten 在当前 oHCM 管理算法中定位相关的问题、与背景治疗的相互作用，以及除了缓解左心室流出道梗阻症状之外改善疾病的潜力。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37804245/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231007180712&v=2.17.9.post6+86293ac">37804245</a> | DOI： <a href=https://doi.org/10.1093/eurheartj/ehad637>10.1093/eurheartj/ehad637</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37804245</guid><pubDate> Sat, 07 Oct 2023 06:00:00 -0400</pubDate><dc:creator>尤金·布劳瓦尔德</dc:creator><dc:creator>萨拉·萨贝里</dc:creator><dc:creator>西奥多·P·亚伯拉罕</dc:creator><dc:creator>佩里·埃利奥特</dc:creator><dc:creator>亚科波·奥利沃托</dc:creator><dc:date>2023-10-07</dc:date><dc:source>欧洲心脏杂志</dc:source><dc:title>Mavacamten：用于治疗梗阻性肥厚性心肌病的一流肌球蛋白抑制剂</dc:title><dc:identifier>下午:37804245</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad637</dc:identifier></item><item><title>围产期心肌病的 20 年人群研究</title><link/>https://pubmed.ncbi.nlm.nih.gov/37804234/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231007180712&amp;v=2.17.9.post6+86293ac<description>结论：PPCM 在怀孕期间影响了 4950 名妇女中的 1 名。这种情况与母亲和儿童的相当大的发病率和死亡率有关。调查高危妇女的门槛应该较低。长期随访，尽管明显恢复，应该考虑。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 年 10 月 7 日：ehad626。doi：10.1093/eurheartj/ehad626。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景和目的：人们对欧洲围产期心肌病 (PPCM) 的流行病学知之甚少，也缺乏长期结果的数据。对 1998 年至 2017 年苏格兰经验证的 PPCM 病例进行了一项回顾性、观察性、人群水平的研究。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：纳入在怀孕期间因推测新发左心室收缩功能障碍而住院且没有明确其他原因的女性。每个病例与 10 名对照者相匹配。确定发病率和危险因素。检查母亲和儿童的发病率和死亡率。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：PPCM 的发生率为 4950 例分娩中 1 例。在 225 名患有 PPCM 的女性中，发现肥胖、妊娠高血压疾病和多胎妊娠与患有该疾病有关。中位时间超过 8.3 年（超声心动图结果为 9.7 年） ），8% 的 PPCM 女性死亡，75% 的女性因任何原因至少再住院一次。PPCM 女性的死亡率和再住院率分别是对照组的约 12 倍和约 3 倍。全因的综合数据死亡、机械循环支持或心脏移植的比例为 14%。左心室恢复的比例为 76%，在康复者中，尽管初步恢复，但仍有 13% 的左心室收缩功能继续下降。患有 PPCM 的女性所生孩子的数量是对照组的 5 倍，并且在中位数 8.8 年内，她们的心血管疾病发病率高出 3 倍。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：PPCM 在怀孕期间影响了 4950 名妇女中的 1 名。这种情况与母亲和儿童的相当大的发病率和死亡率有关。调查高危妇女的门槛应该较低。长期随访，尽管明显恢复，应该考虑。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37804234/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231007180712&v=2.17.9.post6+86293ac">37804234</a> | DOI： <a href=https://doi.org/10.1093/eurheartj/ehad626>10.1093/eurheartj/ehad626</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37804234</guid><pubDate> Sat, 07 Oct 2023 06:00:00 -0400</pubDate><dc:creator>艾丽丝·M·杰克逊</dc:creator><dc:creator>马克·麦戛尔尼</dc:creator><dc:creator>卡特里奥娜·布鲁克斯班克</dc:creator><dc:creator>卡罗琳·布朗</dc:creator><dc:creator>达纳·道森</dc:creator><dc:creator>马克·弗朗西斯</dc:creator><dc:creator>艾伦·贾普</dc:creator><dc:creator>维拉·伦尼</dc:creator><dc:creator>史蒂芬·J·莱斯利</dc:creator><dc:creator>托马斯·马丁</dc:creator><dc:creator>保罗·尼尔里</dc:creator><dc:creator>索米亚·文卡塔苏布拉曼尼安</dc:creator><dc:creator>黛布拉·维克斯</dc:creator><dc:creator>罗宾·威尔</dc:creator><dc:creator>约翰·JV·麦克默里</dc:creator><dc:creator>帕迪普·S·琼德</dc:creator><dc:creator>马克·皮特里</dc:creator><dc:date>2023-10-07</dc:date><dc:source>欧洲心脏杂志</dc:source><dc:title>围产期心肌病的 20 年人群研究</dc:title><dc:identifier>下午:37804234</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad626</dc:identifier></item><item><title>资源有限，指南有限？致力于跨环境提供适当的、因地制宜的心血管护理</title><link/>https://pubmed.ncbi.nlm.nih.gov/37801634/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231007180712&amp;v=2.17.9.post6+86293ac<description>无摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 年 10 月 6 日：ehad253。doi：10.1093/eurheartj/ehad253。印刷前在线。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37801634/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231007180712&v=2.17.9.post6+86293ac">37801634</a> | DOI： <a href=https://doi.org/10.1093/eurheartj/ehad253>10.1093/eurheartj/ehad253</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37801634</guid><pubDate> Fri, 06 Oct 2023 06:00:00 -0400</pubDate><dc:creator>多米尼克·维沃特</dc:creator><dc:date>2023-10-06</dc:date><dc:source>欧洲心脏杂志</dc:source><dc:title>资源有限，指南有限？致力于跨环境提供适当的、因地制宜的心血管护理</dc:title><dc:identifier>下午：37801634</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad253</dc:identifier></item><item><title>近期发作的扩张型心肌病的心肌恢复：&lt;em>;CDCP1&lt;/em>; 与心脏纤维化的作用</title><link/>https://pubmed.ncbi.nlm.nih.gov/37800334/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231007180712&amp;v=2.17.9.post6+86293ac<description>结论：CDCP1 可能在新发 DCM 的心肌恢复中发挥重要作用，并主要通过减轻心脏纤维化来介导其作用。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Circ Res. 2023 年 10 月 6 日。doi：10.1161/CIRCRESAHA.123.323200。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景：扩张型心肌病（DCM）是心力衰竭的主要原因，死亡率很高。DCM相关心力衰竭患者的心肌恢复情况差异很大，一些患者对标准药物治疗反应很少或没有反应。广泛的关联研究可以不可知地识别生物标志物，并为 DCM 心肌恢复的生物学提供新的见解。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：对 686 名接受标准药物治疗的新发 DCM 白人受试者进行了一项针对左心室射血分数变化的全基因组关联研究。随后对全基因组关联研究信号进行了功能验证，并在相关细胞模型中进行了研究，以了解分子机制。可能导致左心室射血分数变化的机制。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：全基因组关联研究确定了一个高度提示性的位点，该位点映射到<i>CDCP1</i> （含有蛋白1的CUB结构域）基因（rs6773435； <i>P</i> =7.12×10 <sup>-</sup> <sup>7</sup> ）的5&#39;侧翼区域。心脏功能得到改善， <i>CDCP1</i>转录减少。CDCP1 表达在人心脏成纤维细胞 (HCF) 中显着上调，以响应 PDGF（血小板源性生长因子）信号传导，敲低 CDCP1 显着抑制 HCF 增殖并降低 AKT 磷酸化。 HCF 中 CDCP1 敲除后的结果支持了 CDCP1 调节 HCF 增殖和有丝分裂的结论。此外，HCF 中 CDCP1 敲除导致可溶性 ST2 的表达显着降低，ST2 是心力衰竭和心脏纤维化诱导物的预后生物标志物。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论： <i>CDCP1</i>可能在新发 DCM 的心肌恢复中发挥重要作用，并主要通过减轻心脏纤维化来介导其作用。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37800334/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231007180712&v=2.17.9.post6+86293ac">37800334</a> | DOI： <a href=https://doi.org/10.1161/CIRCRESAHA.123.323200>10.1161/CIRCRESAHA.123.323200</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37800334</guid><pubDate> Fri, 06 Oct 2023 06:00:00 -0400</pubDate><dc:creator>刘端</dc:creator><dc:creator>王敏</dc:creator><dc:creator>维沙坎塔·穆尔蒂</dc:creator><dc:creator>丹尼斯·M·麦克纳马拉</dc:creator><dc:creator>阮青青</dc:creator><dc:creator>特鲁迪·J·飞利浦</dc:creator><dc:creator>赫里扬舒·维亚斯</dc:creator><dc:creator>高焕耀</dc:creator><dc:creator>乔丹·萨尼</dc:creator><dc:creator>兰德尔·C·斯塔林</dc:creator><dc:creator>莱斯利·T·库珀</dc:creator><dc:creator>米歇尔·K·斯基姆</dc:creator><dc:creator>安东尼·巴茨勒</dc:creator><dc:creator>格雷戈里·D·詹金斯</dc:creator><dc:creator>西蒙娜·巴雷拉</dc:creator><dc:creator>西尔瓦娜·佩莱吉</dc:creator><dc:creator>路易莎·梅斯特罗尼</dc:creator><dc:creator>马可·梅洛</dc:creator><dc:creator>吉安弗兰科·西纳格拉</dc:creator><dc:creator>弗洛伦斯·皮内</dc:creator><dc:creator>扬·克雷吉奇</dc:creator><dc:creator>安娜·查卢普卡</dc:creator><dc:creator>乔丹·D·米勒</dc:creator><dc:creator>帕斯卡·德·格鲁特</dc:creator><dc:creator>丹尼尔·J·楚姆珀林</dc:creator><dc:creator>理查德·M·温希尔博姆</dc:creator><dc:creator>纳文·L·佩雷拉</dc:creator><dc:creator>IMAC-2 调查员</dc:creator><dc:date>2023-10-06</dc:date><dc:source>流通研究</dc:source><dc:title>近期发作的扩张型心肌病的心肌恢复：&lt;em>;CDCP1&lt;/em>; 与心脏纤维化的作用</dc:title><dc:identifier>下午:37800334</dc:identifier><dc:identifier> doi:10.1161/CIRCRESAHA.123.323200</dc:identifier></item><item><title>胱硫醚 γ-裂解酶与 p53 的结合中断促进内皮衰老</title><link/>https://pubmed.ncbi.nlm.nih.gov/37800327/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231007180712&amp;v=2.17.9.post6+86293ac<description>结论：与衰老相关的血管修复损伤部分是由血管保护酶 CSE 决定的。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Circ Res. 2023 年 10 月 6 日。doi：10.1161/CIRCRESAHA.123.323084。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景：高龄与心血管疾病的发展明确相关；然而，导致内皮细胞再生减少的机制仍知之甚少。在这里，我们研究了涉及内皮细胞衰老的新机制，这些机制影响内皮细胞转录和损伤后的血管修复。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：从年轻人（20±3.4岁）和老年人（80±2.3岁）个体中分离天然内皮细胞，并进行分子分析以评估整体转录和代谢变化。使用原代人和小鼠内皮细胞进行体外研究。使用小鼠主动脉再内皮化模型来检查体内内皮细胞的再生能力。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：天然内皮细胞的 RNA 测序显示，衰老导致 p53 介导的重编程，以表达衰老相关基因并抑制糖酵解。葡萄糖摄取和 ATP 的减少导致端粒酶复合物的组装减弱，而端粒酶复合物是内皮细胞增殖所必需的。由于乙酰转移酶 MOZ（单核细胞白血病锌指）活性增强，p53 在衰老过程中的活性与其在 K120 上的乙酰化有关。从机制上讲，p53 乙酰化和易位至少部分归因于血管保护酶 CSE（胱硫醚）的丧失。 CSE 将 p53 物理锚定在细胞质中，以防止其核转位，并且在其缺失的情况下抑制 Akt 介导的 MOZ 磷酸化，从而增加 MOZ 活性和随后的 p53 乙酰化。在小鼠中，CSE 的内皮细胞特异性删除激活了 p53，诱导早熟相比之下，腺相关病毒9介导的活性CSE突变体的重新表达将p53保留在细胞质中，维持内皮葡萄糖代谢和增殖，并防止内皮细胞衰老。来自老年人的天然内皮细胞保持低p53活性并重新激活端粒酶以恢复内皮细胞衰老。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：与衰老相关的血管修复损伤部分是由血管保护酶 CSE 决定的。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37800327/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231007180712&v=2.17.9.post6+86293ac">37800327</a> | DOI： <a href=https://doi.org/10.1161/CIRCRESAHA.123.323084>10.1161/CIRCRESAHA.123.323084</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37800327</guid><pubDate> Fri, 06 Oct 2023 06:00:00 -0400</pubDate><dc:creator>胡炯</dc:creator><dc:creator>马蒂亚斯·莱塞冈</dc:creator><dc:creator>马里奥·卢索</dc:creator><dc:creator>玛丽亚·基里亚基·德雷科利亚</dc:creator><dc:creator>贾尼娜·维蒂格</dc:creator><dc:creator>贾尼娜·梅特纳</dc:creator><dc:creator>克里斯蒂娜·卡兰塔诺</dc:creator><dc:creator>阿纳斯塔西娅·凯塞洛娃</dc:creator><dc:creator>加布里耶拉·邓博维奇</dc:creator><dc:creator>李晓明</dc:creator><dc:creator>李媛媛</dc:creator><dc:creator>斯特凡·根瑟</dc:creator><dc:creator>大卫·约翰</dc:creator><dc:creator>毛罗·西拉古萨</dc:creator><dc:creator>斯文·祖昆夫特</dc:creator><dc:creator>詹姆斯·欧</dc:creator><dc:creator>伊尔卡·维蒂格</dc:creator><dc:creator>苏珊娜·希勒</dc:creator><dc:creator>安德烈亚斯·魏格特</dc:creator><dc:creator>斯特凡·纳普</dc:creator><dc:creator>拉尔夫·P·布兰德斯</dc:creator><dc:creator>奥利弗·J·穆勒</dc:creator><dc:creator>安德烈亚斯·帕帕佩特罗普洛斯</dc:creator><dc:creator>弗拉吉斯卡·西加拉</dc:creator><dc:creator>格尔加娜·多布雷娃</dc:creator><dc:creator>巴克特别克·科乔纳扎罗夫</dc:creator><dc:creator>英格丽·弗莱明</dc:creator><dc:creator>索菲亚·艾里斯·比卜利</dc:creator><dc:date>2023-10-06</dc:date><dc:source>流通研究</dc:source><dc:title>胱硫醚 γ-裂解酶与 p53 的结合中断促进内皮衰老</dc:title><dc:identifier>下午:37800327</dc:identifier><dc:identifier> doi:10.1161/CIRCRESAHA.123.323084</dc:identifier></item><item><title>脑内皮：脑小血管疾病的纽带</title><link/>https://pubmed.ncbi.nlm.nih.gov/37798089/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231007180712&amp;v=2.17.9.post6+86293ac<description>无摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 年 8 月 29 日：ehad526。doi：10.1093/eurheartj/ehad526。印刷前在线。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37798089/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231007180712&v=2.17.9.post6+86293ac">37798089</a> | DOI： <a href=https://doi.org/10.1093/eurheartj/ehad526>10.1093/eurheartj/ehad526</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37798089</guid><pubDate> Thu, 05 Oct 2023 06:00:00 -0400</pubDate><dc:creator>马丁·迪奇甘斯</dc:creator><dc:creator>弗兰克·M·法拉奇</dc:creator><dc:creator>布伦达网络</dc:creator><dc:date>2023-10-05</dc:date><dc:source>欧洲心脏杂志</dc:source><dc:title>脑内皮：脑小血管疾病的纽带</dc:title><dc:identifier>下午:37798089</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad526</dc:identifier></item><item><title>欧洲心脏病学会心血管药物治疗工作组</title><link/>https://pubmed.ncbi.nlm.nih.gov/37796825/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231007180712&amp;v=2.17.9.post6+86293ac<description>无摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 年 10 月 4 日：ehad651。doi：10.1093/eurheartj/ehad651。印刷前在线。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37796825/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231007180712&v=2.17.9.post6+86293ac">37796825</a> | DOI： <a href=https://doi.org/10.1093/eurheartj/ehad651>10.1093/eurheartj/ehad651</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37796825</guid><pubDate> Thu, 05 Oct 2023 06:00:00 -0400</pubDate><dc:creator>胡安·卡洛斯·卡斯基</dc:creator><dc:creator>亚历山大·尼斯纳</dc:creator><dc:creator>多布罗米尔·多布雷夫</dc:creator><dc:creator>比安卡·罗卡</dc:creator><dc:date>2023-10-05</dc:date><dc:source>欧洲心脏杂志</dc:source><dc:title>欧洲心脏病学会心血管药物治疗工作组</dc:title><dc:identifier>下午:37796825</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad651</dc:identifier></item><item><title>肥厚型心肌病晚期钆增强评估可根据现行指南改善风险分层</title><link/>https://pubmed.ncbi.nlm.nih.gov/37795986/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231007180712&amp;v=2.17.9.post6+86293ac<description>结论：2022 年 ESC 模型的表现优于 2014 年 ESC 模型，灵敏度尤其提高。LGE 能够根据当前指南进行进一步的风险分层。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 年 10 月 5 日：ehad581。doi：10.1093/eurheartj/ehad581。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景和目的：确定适合植入式心律转复除颤器 (ICD) 植入的肥厚型心肌病 (HCM) 患者在心源性猝死 (SCD) 一级预防中至关重要。本研究的目的是从外部验证 2022 年欧洲心脏协会心脏病学 (ESC) 模型和其他基于指南的 ICD 推荐类别 (ICD-COR) 模型，并探索晚期钆增强 (LGE) 在进一步风险分层中的效用。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：回顾性纳入 774 名连续接受心脏磁共振成像的患者。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：46 名 (5.9%) 患者在 7.4 ± 2.5 年的随访期间达到了 SCD 相关终点。患有 SCD 的患者具有较高的 ESC 风险-SCD 评分（4.3 ± 2.4% vs. 2.8 ± 2.1%，P &lt; .001) 和 LGE 范围 (13.7 ± 9.4% vs. 4.9 ± 6.6%, P &lt; .001)。与 2014 年 ESC 模型相比，2022 年 ESC 模型的曲线下面积有所增加 (.76 vs. .63) 、敏感性（76.1% vs. 43.5%）、阳性预测值（16.8% vs. 13.6%）和阴性预测值（98.1% vs. 95.9%）。2011 年美国心脏病学会 SCD 预测的 C 统计量（ ACC)/美国心脏协会 (AHA)，2014 ESC、2020 AHA/ACC 和 2022 ESC 模型分别为 0.68、0.64、0.76 和 0.78。此外，在没有广泛 LGE 的患者中，LGE ≥5% 为多变量调整后，SCD 风险增加了 7 倍。无论是 ICD-COR II 还是 ICD-COR III，LGE ≥5% 和 &lt;15% 的患者预后明显比 LGE &lt;5% 的患者差（所有 P &lt; .001） ）。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：2022 年 ESC 模型的表现优于 2014 年 ESC 模型，灵敏度尤其提高。LGE 能够根据当前指南进行进一步的风险分层。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37795986/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231007180712&v=2.17.9.post6+86293ac">37795986</a> | DOI： <a href=https://doi.org/10.1093/eurheartj/ehad581>10.1093/eurheartj/ehad581</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37795986</guid><pubDate> Thu, 05 Oct 2023 06:00:00 -0400</pubDate><dc:creator>王嘉欣</dc:creator><dc:creator>杨淑娟</dc:creator><dc:creator>马轩</dc:creator><dc:creator>赵侃侃</dc:creator><dc:creator>杨凯</dc:creator><dc:creator>于士钦</dc:creator><dc:creator>尹刚</dc:creator><dc:creator>董志祥</dc:creator><dc:creator>宋艳艳</dc:creator><dc:creator>崔陈</dc:creator><dc:creator>李景辉</dc:creator><dc:creator>王创世</dc:creator><dc:creator>俊浩</dc:creator><dc:creator>民街路民街路</dc:creator><dc:creator>陈秀玉</dc:creator><dc:creator>赵世华</dc:creator><dc:date>2023-10-05</dc:date><dc:source>欧洲心脏杂志</dc:source><dc:title>肥厚型心肌病晚期钆增强评估可根据现行指南改善风险分层</dc:title><dc:identifier>下午:37795986</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad581</dc:identifier></item><item><title>非牙科侵入性手术和感染性心内膜炎的风险：重新审视的时间：美国心脏协会的科学建议</title><link/>https://pubmed.ncbi.nlm.nih.gov/37795631/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231007180712&amp;v=2.17.9.post6+86293ac<description>目前尚无已发表的前瞻性随机临床试验表明：(1) 确定了侵入性牙科和非牙科侵入性操作与感染性心内膜炎风险之间的关联；或 (2) 明确了在侵入性操作中使用抗生素预防的有效性和安全性预防高危患者感染性心内膜炎。此外，之前的观察性研究检验了非牙科侵入性操作与...的关系。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通</b>。2023 年 10 月 5 日。doi：10.1161/CIR.0000000000001180。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">目前尚无已发表的前瞻性随机临床试验表明：(1) 确定了侵入性牙科和非牙科侵入性操作与感染性心内膜炎风险之间的关联；或 (2) 明确了在侵入性操作中使用抗生素预防的有效性和安全性预防高危患者感染性心内膜炎。此外，之前检查非牙科侵入性操作与感染性心内膜炎风险之间关系的观察性研究因样本量不足而受到限制。他们通常关注一些潜在的高危人群然而，瑞典和英国最近使用全国数据库进行的调查表明，非牙科侵入性操作与感染性心内膜炎的后续发展（特别是感染性心内膜炎的高危患者）之间存在关联，促进了这一发展当前的科学咨询。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37795631/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231007180712&v=2.17.9.post6+86293ac">37795631</a> | DOI： <a href=https://doi.org/10.1161/CIR.0000000000001180>10.1161/CIR.0000000000001180</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37795631</guid><pubDate> Thu, 05 Oct 2023 06:00:00 -0400</pubDate><dc:creator>拉里·M·巴杜尔</dc:creator><dc:creator>伊姆雷·詹斯基</dc:creator><dc:creator>马丁·H·桑希尔</dc:creator><dc:creator>泽瑞尔达·埃斯奎尔·加里戈斯</dc:creator><dc:creator>丹尼尔·C·德西蒙</dc:creator><dc:creator>凯伦·韦尔蒂-沃尔夫</dc:creator><dc:creator>安妮特·L·贝克</dc:creator><dc:creator>琼斯佩妮</dc:creator><dc:creator>伯纳德·普伦德加斯特</dc:creator><dc:creator>马克·J·戴尔</dc:creator><dc:creator>美国心脏协会终身先天性心脏病和年轻人心脏健康委员会以及心血管和中风护理委员会</dc:creator><dc:date>2023-10-05</dc:date><dc:source>循环</dc:source><dc:title>非牙科侵入性手术和感染性心内膜炎的风险：重新审视的时间：美国心脏协会的科学建议</dc:title><dc:identifier>下午:37795631</dc:identifier><dc:identifier>号码：10.1161/CIR.0000000000001180</dc:identifier></item><item><title> HLHS 儿童的纵向随访以及诺伍德分流类型与长期结果之间的关联：SVRIII 研究</title><link/>https://pubmed.ncbi.nlm.nih.gov/37795623/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231007180712&amp;v=2.17.9.post6+86293ac<description>结论：到诺伍德手术后 12 年，分流类型与 RVEF、峰值 Vo(2)、并发症发生率和无移植生存率的相关性极小。在接受 CMR 评估的幸存者亚组中，RVEF 得到保留。生存率、运动表现不佳和发病率不断上升，凸显了需要创新策略来改善左心发育不全综合征患者的长期预后。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通</b>。2023 年 10 月 5 日。doi：10.1161/CIRCULATIONAHA.123.065192。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">目的：在 SVR 试验（单心室重建）中，患有左心发育不良综合征的新生儿在诺伍德手术中被随机分配接受改良的 Blalock-Taussig-Thomas 分流术 (mBTTS) 或右心室至肺动脉分流术 (RVPAS) RVPAS 组在 1 年时的无移植生存率较高，但在 6 年时治疗组的无移植生存率不再有差异；两个治疗组都积累了重要的发病率。在该队列的第三次随访中（SVRIII [长期结果患有左心发育不良综合征的儿童和诺伍德分流类型的影响]），我们测量了 12 岁的纵向结果及其风险因素。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：通过记录审查和电话访谈收集年度病史。对患有 Fontan 生理学的参与者在 10 至 14 岁时进行心脏磁共振成像 (CMR)、超声心动图和自行车测功心肺运动测试。生存率和并发症发生率（例如，心律失常或蛋白质丢失性肠病）在 12 岁之前确定。主要研究结果是通过 CMR 测得的右心室射血分数 (RVEF)，主要分析根据收到的分流类型进行。多变量线性和通过 CMR 和 Fontan 移植后生存率创建 RVEF 的 Cox 回归模型。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：在参加 SVR 的 549 名参与者中，313 名（76%；60.7% 男性）无移植幸存者中的 237 名（mBTTS，147 名中的 105 名；RVPAS，161 名中的 129 名；均为 5 名中的 3 名）参加了 SVRIII。根据 CMR 计算的 RVEF分流组的情况相似（RVPAS，51±9.6 [n=90]，mBTTS，52±7.4 [n=75]； <i>P</i> = 0.43）。RVPAS 和 mBTTS 组的无移植生存率没有差异 12年龄（分别为 277 人中的 163 人 [59%] 与 267 人中的 144 人 [54%]； <i>P</i> = 0.11），年龄和性别的预测峰值 Vo <sub>2</sub>百分比（74±18% [n=91] 与 72±18） % [n=84]； <i>P</i> =0.71），或按体型和性别预测工作率的百分比（65±20% 与 64±19%； <i>P</i> =0.65）。RVPAS 组与 mBTTS 组相比，蛋白质累积发生率更高肠病（5% vs 2%； <i>P</i> = 0.04）和导管干预（每 100 患者年 14 例 vs 10 例； <i>P</i> = 0.01）消失，但其他并发症的发生率相似。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：到 Norwood 手术后 12 年，分流类型与 RVEF、峰值 Vo <sub>2</sub> 、并发症发生率和无移植生存率的相关性极小。在接受 CMR 评估的幸存者亚组中，RVEF 得到保留。低无移植生存率，运动表现不佳和不断增加的发病率凸显了需要创新策略来改善左心发育不全综合征患者的长期预后。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">注册：网址：https://www. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">临床试验：gov；唯一标识符：NCT00115934。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37795623/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231007180712&v=2.17.9.post6+86293ac">37795623</a> | DOI： <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.065192>10.1161/CIRCULATIONAHA.123.065192</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37795623</guid><pubDate> Thu, 05 Oct 2023 06:00:00 -0400</pubDate><dc:creator>卡伦·戈德堡</dc:creator><dc:creator>费利西亚·特拉亨伯格</dc:creator><dc:creator>J·威廉·盖纳</dc:creator><dc:creator>威廉·T·马勒</dc:creator><dc:creator>奇特拉·拉维尚卡</dc:creator><dc:creator>史蒂文·M·施瓦茨</dc:creator><dc:creator>詹姆斯·F·克诺塔</dc:creator><dc:creator>理查德·G·奥耶</dc:creator><dc:creator>拉塞尔·贡维尔</dc:creator><dc:creator>迈克尔·泰勒</dc:creator><dc:creator>史蒂芬·帕里登</dc:creator><dc:creator>彼得·C·弗罗梅尔特</dc:creator><dc:creator>凯瑟琳·阿夫顿</dc:creator><dc:creator>安德鲁·M·阿兹</dc:creator><dc:creator>克里斯汀·M·伯恩斯</dc:creator><dc:creator>乔恩·德特里奇</dc:creator><dc:creator>凯文·D·希尔</dc:creator><dc:creator>安东尼奥·G·卡布雷拉</dc:creator><dc:creator>艾伦·B·刘易斯</dc:creator><dc:creator>克里斯蒂安·皮萨罗</dc:creator><dc:creator>阿米·沙阿</dc:creator><dc:creator>比努·夏尔马</dc:creator><dc:creator>简·W·纽伯格</dc:creator><dc:creator>儿科心脏网络调查员</dc:creator><dc:date>2023-10-05</dc:date><dc:source>循环</dc:source><dc:title>HLHS 儿童的纵向随访以及诺伍德分流类型与长期结果之间的关联：SVRIII 研究</dc:title><dc:identifier>下午:37795623</dc:identifier><dc:identifier> doi:10.1161/循环AHA.123.065192</dc:identifier></item><item><title>心绞痛且无阻塞性冠状动脉疾病患者的侵入性内分型：一项随机对照试验</title><link/>https://pubmed.ncbi.nlm.nih.gov/37795617/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231007180712&amp;v=2.17.9.post6+86293ac<description>结论：对于心绞痛且冠状动脉无阻塞的患者，侵入性功能评估的诊断对长期心绞痛负担没有影响，而治疗满意度有所提高。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通</b>。2023 年 10 月 5 日。doi：10.1161/CIRCULATIONAHA.123.064751。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景：我们研究了侵入性冠状动脉功能测试对于诊断无阻塞冠状动脉患者心绞痛原因的有用性。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：对英国3家医院转诊进行冠状动脉CT血管造影的门诊患者进行前瞻性筛查。冠状动脉CT血管造影后，冠状动脉通畅且同意的患者接受侵入性内分型。诊断评估包括冠状动脉造影、血流储备分数（如果≤0.80，则排除患者），对于没有阻塞性冠状动脉疾病的患者，还需检查冠状动脉血流储备（异常&lt;2.0）、微血管阻力指数（异常≥25）和冠状动脉内输注乙酰胆碱（0.182、1.82和18.2μg） /mL；2 mL/min，持续 2 分钟）以评估微血管和冠状动脉痉挛。参与者被随机分配向侵入性心脏病专家披露冠状动脉功能测试结果（干预组）或不披露（对照组，盲法）。在对照组中，血管舒缩性心绞痛的诊断基于病史、无创检查和冠状动脉造影。主要结果是基于冠状动脉计算机断层扫描的初始诊断的重新分类率与最终诊断的重新分类率的组间差异。侵入性内分型后诊断。西雅图心绞痛问卷总结评分和药物治疗满意度调查问卷是次要结果。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：在 322 名符合条件的患者中，250 名（77.6%）接受了侵入性内分型；19 名（7.6%）患有阻塞性冠状动脉疾病，127 名（55.0%）患有微血管心绞痛，27 名（11.7%）患有血管痉挛性心绞痛，17 名（7.4%）患有血管性心绞痛。两者皆有，60 例 (26.0%) 无异常。共有 231 例患者（平均年龄，55.7 岁；64.5% 女性）被随机分配并随访（中位持续时间，19.9 [12.6-26.9] 个月）。临床医生诊断干预组有 51 名 (44.3%) 患者出现血管舒缩性心绞痛，对照组有 55 名 (47.4%) 患者出现血管舒缩性心绞痛。随机化后，干预组患者出现血管舒缩性心绞痛的比例是 4 倍（比值比，4.05 [95% CI，2.32- 7.24]； <i>P</i> &lt;0.001）更有可能被诊断为冠状动脉血管舒缩障碍；该诊断的频率增加至 76.5%。随机分组前，各组之间冠状动脉功能正常（即无血管舒缩障碍）的频率没有差异（ 51.3% 对比 50.9%），但随机化后干预组有所下降（23.5% 对比 50.9%， <i>P</i> &lt;0.001）。在 6 个月和 12 个月时，干预组与对照组的西雅图心绞痛问卷总分分别为 59.2±24.2（相对于基线的变化为 2.3±16.2）与 60.4±23.9（4.6±16.4 变化）和 63.7±23.5（4.7±14.7 变化）与 66.0±19.3（7.9±17.1 变化），组间无差异（总体<i>P</i> =0.36） ).与对照组相比，干预组12个月时总体治疗满意度较高（69.9±22.8 vs 61.7±26.9， <i>P</i> =0.013）。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> CONCLUSIONS: For patients with angina and no obstructive coronary arteries, a diagnosis informed by invasive functional assessment had no effect on long-term angina burden, whereas treatment satisfaction improved. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> REGISTRATION: URL: https://www. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> CLINICALTRIALS: gov; Unique identifier: NCT03477890.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37795617/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231007180712&v=2.17.9.post6+86293ac">37795617</a> | DOI: <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.064751>10.1161/CIRCULATIONAHA.123.064751</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37795617</guid><pubDate> Thu, 05 Oct 2023 06:00:00 -0400</pubDate><dc:creator> Novalia P Sidik</dc:creator><dc:creator> Bethany Stanley</dc:creator><dc:creator> Robert Sykes</dc:creator><dc:creator> Andrew J Morrow</dc:creator><dc:creator> Conor P Bradley</dc:creator><dc:creator> Michael McDermott</dc:creator><dc:creator> Thomas J Ford</dc:creator><dc:creator> Giles Roditi</dc:creator><dc:creator> Allister Hargreaves</dc:creator><dc:creator> David Stobo</dc:creator><dc:creator> Jacqueline Adams</dc:creator><dc:creator> John Byrne</dc:creator><dc:creator> Ahmed Mahrous</dc:creator><dc:creator> Robin Young</dc:creator><dc:creator> David Carrick</dc:creator><dc:creator> Ross McGeoch</dc:creator><dc:creator> David Corcoran</dc:creator><dc:creator> Ninian N Lang</dc:creator><dc:creator> Robert Heggie</dc:creator><dc:creator> Olivia Wu</dc:creator><dc:creator> Margaret B McEntegart</dc:creator><dc:creator> Alex McConnachie</dc:creator><dc:creator> Colin Berry</dc:creator><dc:date> 2023-10-05</dc:date><dc:source> Circulation</dc:source><dc:title> Invasive Endotyping in Patients With Angina and No Obstructive Coronary Artery Disease: A Randomized Controlled Trial</dc:title><dc:identifier> pmid:37795617</dc:identifier><dc:identifier> doi:10.1161/CIRCULATIONAHA.123.064751</dc:identifier></item><item><title> Auditory stimulation of sleep slow waves enhances left ventricular function in humans</title><link/> https://pubmed.ncbi.nlm.nih.gov/37794725/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231007180712&amp;v=2.17.9.post6+86293ac<description> No abstract </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 Oct 5:ehad630. doi: 10.1093/eurheartj/ehad630. Online ahead of print.</p><p> <b>NO ABSTRACT</b></p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37794725/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231007180712&v=2.17.9.post6+86293ac">37794725</a> | DOI: <a href=https://doi.org/10.1093/eurheartj/ehad630>10.1093/eurheartj/ehad630</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37794725</guid><pubDate> Thu, 05 Oct 2023 06:00:00 -0400</pubDate><dc:creator> Stephanie Huwiler</dc:creator><dc:creator> Manuel Carro-Domínguez</dc:creator><dc:creator> Fabia M Stich</dc:creator><dc:creator> Rossella Sala</dc:creator><dc:creator> Florent Aziri</dc:creator><dc:creator> Anna Trippel</dc:creator><dc:creator> Tabea Ryf</dc:creator><dc:creator> Susanne Markendorf</dc:creator><dc:creator> David Niederseer</dc:creator><dc:creator> Philipp Bohm</dc:creator><dc:creator> Gloria Stoll</dc:creator><dc:creator> Lily Laubscher</dc:creator><dc:creator> Jeivicaa Thevan</dc:creator><dc:creator> Christina M Spengler</dc:creator><dc:creator> Joanna Gawinecka</dc:creator><dc:creator> Elena Osto</dc:creator><dc:creator> Reto Huber</dc:creator><dc:creator> Nicole Wenderoth</dc:creator><dc:creator> Christian Schmied</dc:creator><dc:creator> Caroline Lustenberger</dc:creator><dc:date> 2023-10-05</dc:date><dc:source> European heart journal</dc:source><dc:title> Auditory stimulation of sleep slow waves enhances left ventricular function in humans</dc:title><dc:identifier> pmid:37794725</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad630</dc:identifier></item><item><title> Medicine at the dawn of the metaclinical era</title><link/> https://pubmed.ncbi.nlm.nih.gov/37794638/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231007180712&amp;v=2.17.9.post6+86293ac<description> No abstract </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 Oct 5:ehad599. doi: 10.1093/eurheartj/ehad599. Online ahead of print.</p><p> <b>NO ABSTRACT</b></p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37794638/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231007180712&v=2.17.9.post6+86293ac">37794638</a> | DOI: <a href=https://doi.org/10.1093/eurheartj/ehad599>10.1093/eurheartj/ehad599</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37794638</guid><pubDate> Thu, 05 Oct 2023 06:00:00 -0400</pubDate><dc:creator> Panos E Vardas</dc:creator><dc:creator> Emmanouil P Vardas</dc:creator><dc:creator> Stylianos Tzeis</dc:creator><dc:date> 2023-10-05</dc:date><dc:source> European heart journal</dc:source><dc:title> Medicine at the dawn of the metaclinical era</dc:title><dc:identifier> pmid:37794638</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad599</dc:identifier></item><item><title> When technology innovation is the only path to treat patients in economic crisis countries: the Syrian experience</title><link/> https://pubmed.ncbi.nlm.nih.gov/37794637/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231007180712&amp;v=2.17.9.post6+86293ac<description> No abstract </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 Oct 5:ehad634. doi: 10.1093/eurheartj/ehad634. Online ahead of print.</p><p> <b>NO ABSTRACT</b></p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37794637/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231007180712&v=2.17.9.post6+86293ac">37794637</a> | DOI: <a href=https://doi.org/10.1093/eurheartj/ehad634>10.1093/eurheartj/ehad634</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37794637</guid><pubDate> Thu, 05 Oct 2023 06:00:00 -0400</pubDate><dc:creator> Amr Abdin</dc:creator><dc:creator> Asim Katbeh</dc:creator><dc:creator> Yassin Bani Marjeh</dc:creator><dc:date> 2023-10-05</dc:date><dc:source> European heart journal</dc:source><dc:title> When technology innovation is the only path to treat patients in economic crisis countries: the Syrian experience</dc:title><dc:identifier> pmid:37794637</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad634</dc:identifier></item><item><title> Towards personalized cardiovascular care: Global Registry of Acute Coronary Events 3.0 score heralds artificial intelligence era</title><link/> https://pubmed.ncbi.nlm.nih.gov/37794616/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231007180712&amp;v=2.17.9.post6+86293ac<description> No abstract </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 Oct 5:ehad597. doi: 10.1093/eurheartj/ehad597. Online ahead of print.</p><p> <b>NO ABSTRACT</b></p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37794616/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231007180712&v=2.17.9.post6+86293ac">37794616</a> | DOI: <a href=https://doi.org/10.1093/eurheartj/ehad597>10.1093/eurheartj/ehad597</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37794616</guid><pubDate> Thu, 05 Oct 2023 06:00:00 -0400</pubDate><dc:creator> Florian A Wenzl</dc:creator><dc:creator> Keith AA Fox</dc:creator><dc:creator> Thomas F Lüscher</dc:creator><dc:date> 2023-10-05</dc:date><dc:source> European heart journal</dc:source><dc:title> Towards personalized cardiovascular care: Global Registry of Acute Coronary Events 3.0 score heralds artificial intelligence era</dc:title><dc:identifier> pmid:37794616</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad597</dc:identifier></item><item><title> Mitigation of chromosome loss in clinical CRISPR-Cas9-engineered T cells</title><link/> https://pubmed.ncbi.nlm.nih.gov/37794590/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231007180712&amp;v=2.17.9.post6+86293ac<description> CRISPR-Cas9 genome editing has enabled advanced T cell therapies, but occasional loss of the targeted chromosome remains a safety concern. To investigate whether Cas9-induced chromosome loss is a universal phenomenon and evaluate its clinical significance, we conducted a systematic analysis in primary human T cells. Arrayed and pooled CRISPR screens revealed that chromosome loss was generalizable across the genome and resulted in partial and entire loss of the targeted chromosome, including in... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Cell</b> . 2023 Sep 27:S0092-8674(23)00975-3. doi: 10.1016/j.cell.2023.08.041. Online ahead of print.</p><p> <b>ABSTRACT</b> </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> CRISPR-Cas9 genome editing has enabled advanced T cell therapies, but occasional loss of the targeted chromosome remains a safety concern. To investigate whether Cas9-induced chromosome loss is a universal phenomenon and evaluate its clinical significance, we conducted a systematic analysis in primary human T cells. Arrayed and pooled CRISPR screens revealed that chromosome loss was generalizable across the genome and resulted in partial and entire loss of the targeted chromosome, including in preclinical chimeric antigen receptor T cells. T cells with chromosome loss persisted for weeks in culture, implying the potential to interfere with clinical use. A modified cell manufacturing process, employed in our first-in-human clinical trial of Cas9-engineered T cells (NCT03399448), reduced chromosome loss while largely preserving genome editing efficacy. Expression of p53 correlated with protection from chromosome loss observed in this protocol, suggesting both a mechanism and strategy for T cell engineering that mitigates this genotoxicity in the clinic.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37794590/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231007180712&v=2.17.9.post6+86293ac">37794590</a> | DOI: <a href=https://doi.org/10.1016/j.cell.2023.08.041>10.1016/j.cell.2023.08.041</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37794590</guid><pubDate> Thu, 05 Oct 2023 06:00:00 -0400</pubDate><dc:creator> Connor A Tsuchida</dc:creator><dc:creator> Nadav Brandes</dc:creator><dc:creator> Raymund Bueno</dc:creator><dc:creator> Marena Trinidad</dc:creator><dc:creator> Thomas Mazumder</dc:creator><dc:creator> Bingfei Yu</dc:creator><dc:creator> Byungjin Hwang</dc:creator><dc:creator> Christopher Chang</dc:creator><dc:creator> Jamin Liu</dc:creator><dc:creator> Yang Sun</dc:creator><dc:creator> Caitlin R Hopkins</dc:creator><dc:creator> Kevin R Parker</dc:creator><dc:creator> Yanyan Qi</dc:creator><dc:creator> Laura Hofman</dc:creator><dc:creator> Ansuman T Satpathy</dc:creator><dc:creator> Edward A Stadtmauer</dc:creator><dc:creator> Jamie HD Cate</dc:creator><dc:creator> Justin Eyquem</dc:creator><dc:creator> Joseph A Fraietta</dc:creator><dc:creator> Carl H June</dc:creator><dc:creator> Howard Y Chang</dc:creator><dc:creator> Chun Jimmie Ye</dc:creator><dc:creator> Jennifer A Doudna</dc:creator><dc:date> 2023-10-05</dc:date><dc:source> Cell</dc:source><dc:title> Mitigation of chromosome loss in clinical CRISPR-Cas9-engineered T cells</dc:title><dc:identifier> pmid:37794590</dc:identifier><dc:identifier> doi:10.1016/j.cell.2023.08.041</dc:identifier></item><item><title> SND1 binds SARS-CoV-2 negative-sense RNA and promotes viral RNA synthesis through NSP9</title><link/> https://pubmed.ncbi.nlm.nih.gov/37794589/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231007180712&amp;v=2.17.9.post6+86293ac<description> Regulation of viral RNA biogenesis is fundamental to productive SARS-CoV-2 infection. To characterize host RNA-binding proteins (RBPs) involved in this process, we biochemically identified proteins bound to genomic and subgenomic SARS-CoV-2 RNAs. We find that the host protein SND1 binds the 5&#39; end of negative-sense viral RNA and is required for SARS-CoV-2 RNA synthesis. SND1-depleted cells form smaller replication organelles and display diminished virus growth kinetics. We discover that NSP9, a... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Cell</b> . 2023 Sep 28:S0092-8674(23)00980-7. doi: 10.1016/j.cell.2023.09.002. Online ahead of print.</p><p> <b>ABSTRACT</b> </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> Regulation of viral RNA biogenesis is fundamental to productive SARS-CoV-2 infection. To characterize host RNA-binding proteins (RBPs) involved in this process, we biochemically identified proteins bound to genomic and subgenomic SARS-CoV-2 RNAs. We find that the host protein SND1 binds the 5&#39; end of negative-sense viral RNA and is required for SARS-CoV-2 RNA synthesis. SND1-depleted cells form smaller replication organelles and display diminished virus growth kinetics. We discover that NSP9, a viral RBP and direct SND1 interaction partner, is covalently linked to the 5&#39; ends of positive- and negative-sense RNAs produced during infection. These linkages occur at replication-transcription initiation sites, consistent with NSP9 priming viral RNA synthesis. Mechanistically, SND1 remodels NSP9 occupancy and alters the covalent linkage of NSP9 to initiating nucleotides in viral RNA. Our findings implicate NSP9 in the initiation of SARS-CoV-2 RNA synthesis and unravel an unsuspected role of a cellular protein in orchestrating viral RNA production.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37794589/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231007180712&v=2.17.9.post6+86293ac">37794589</a> | DOI: <a href=https://doi.org/10.1016/j.cell.2023.09.002>10.1016/j.cell.2023.09.002</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37794589</guid><pubDate> Thu, 05 Oct 2023 06:00:00 -0400</pubDate><dc:creator> Nora Schmidt</dc:creator><dc:creator> Sabina Ganskih</dc:creator><dc:creator> Yuanjie Wei</dc:creator><dc:creator> Alexander Gabel</dc:creator><dc:creator> Sebastian Zielinski</dc:creator><dc:creator> Hasmik Keshishian</dc:creator><dc:creator> Caleb A Lareau</dc:creator><dc:creator> Liv Zimmermann</dc:creator><dc:creator> Jana Makroczyova</dc:creator><dc:creator> Cadence Pearce</dc:creator><dc:creator> Karsten Krey</dc:creator><dc:creator> Thomas Hennig</dc:creator><dc:creator> Sebastian Stegmaier</dc:creator><dc:creator> Lambert Moyon</dc:creator><dc:creator> Marc Horlacher</dc:creator><dc:creator> Simone Werner</dc:creator><dc:creator> Jens Aydin</dc:creator><dc:creator> Marco Olguin-Nava</dc:creator><dc:creator> Ramya Potabattula</dc:creator><dc:creator> Anuja Kibe</dc:creator><dc:creator> Lars Dölken</dc:creator><dc:creator> Redmond P Smyth</dc:creator><dc:creator> Neva Caliskan</dc:creator><dc:creator> Annalisa Marsico</dc:creator><dc:creator> Christine Krempl</dc:creator><dc:creator> Jochen Bodem</dc:creator><dc:creator> Andreas Pichlmair</dc:creator><dc:creator> Steven A Carr</dc:creator><dc:creator> Petr Chlanda</dc:creator><dc:creator> Florian Erhard</dc:creator><dc:creator> Mathias Munschauer</dc:creator><dc:date> 2023-10-05</dc:date><dc:source> Cell</dc:source><dc:title> SND1 binds SARS-CoV-2 negative-sense RNA and promotes viral RNA synthesis through NSP9</dc:title><dc:identifier> pmid:37794589</dc:identifier><dc:identifier> doi:10.1016/j.cell.2023.09.002</dc:identifier></item><item><title> Retraction of: Cardiovascular risk profile of a young adult population with high risk for obstructive sleep apnea screened by Stop-Bang and Epworth sleepiness scale in a primary health care unit</title><link/> https://pubmed.ncbi.nlm.nih.gov/37793986/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231007180712&amp;v=2.17.9.post6+86293ac<description> No abstract </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 Oct 5:ehad580. doi: 10.1093/eurheartj/ehad580. Online ahead of print.</p><p> <b>NO ABSTRACT</b></p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37793986/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231007180712&v=2.17.9.post6+86293ac">37793986</a> | DOI: <a href=https://doi.org/10.1093/eurheartj/ehad580>10.1093/eurheartj/ehad580</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37793986</guid><pubDate> Wed, 04 Oct 2023 06:00:00 -0400</pubDate><dc:date> 2023-10-04</dc:date><dc:source> European heart journal</dc:source><dc:title> Retraction of: Cardiovascular risk profile of a young adult population with high risk for obstructive sleep apnea screened by Stop-Bang and Epworth sleepiness scale in a primary health care unit</dc:title><dc:identifier> pmid:37793986</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad580</dc:identifier></item><item><title> KDIGO or UACR: Which Is Key in Affecting Efficacy of SGLT2i in Patients With HF?</title><link/> https://pubmed.ncbi.nlm.nih.gov/37793755/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231007180712&amp;v=2.17.9.post6+86293ac<description> No abstract </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol. 2023 Oct 10;82(15):e135-e136. doi: 10.1016/j.jacc.2023.06.051.</p><p> <b>NO ABSTRACT</b></p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37793755/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231007180712&v=2.17.9.post6+86293ac">37793755</a> | DOI: <a href=https://doi.org/10.1016/j.jacc.2023.06.051>10.1016/j.jacc.2023.06.051</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37793755</guid><pubDate> Wed, 04 Oct 2023 06:00:00 -0400</pubDate><dc:creator> Xiaoqun Xu</dc:creator><dc:creator> Houyong Zhu</dc:creator><dc:creator> Long Cai</dc:creator><dc:creator> Tielong Chen</dc:creator><dc:creator> Kaiqing Lin</dc:creator><dc:date> 2023-10-04</dc:date><dc:source> Journal of the American College of Cardiology</dc:source><dc:title> KDIGO or UACR: Which Is Key in Affecting Efficacy of SGLT2i in Patients With HF?</dc:title><dc:identifier> pmid:37793755</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.06.051</dc:identifier></item><item><title> Empagliflozin in Patients With Heart Failure: Efficacy and Safety Concerns Across Kidney Risk Categories</title><link/> https://pubmed.ncbi.nlm.nih.gov/37793754/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231007180712&amp;v=2.17.9.post6+86293ac<description> No abstract </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol. 2023 Oct 10;82(15):e133. doi: 10.1016/j.jacc.2023.06.052.</p><p> <b>NO ABSTRACT</b></p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37793754/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231007180712&v=2.17.9.post6+86293ac">37793754</a> | DOI: <a href=https://doi.org/10.1016/j.jacc.2023.06.052>10.1016/j.jacc.2023.06.052</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37793754</guid><pubDate> Wed, 04 Oct 2023 06:00:00 -0400</pubDate><dc:creator> Yuzuru Ohshiro</dc:creator><dc:date> 2023-10-04</dc:date><dc:source> Journal of the American College of Cardiology</dc:source><dc:title> Empagliflozin in Patients With Heart Failure: Efficacy and Safety Concerns Across Kidney Risk Categories</dc:title><dc:identifier> pmid:37793754</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.06.052</dc:identifier></item></channel></rss>